 Home > Medical News > Latest Medical News > AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review

AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review

 Last Update: 2022-05-20
 Source: Internet
 Author: User

Tags

nzt 48 review

herpes type 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, AstraZeneca and Daiichi Sankyo jointly announced that the supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan), their jointly developed antibody drug conjugate (ADC), has been granted by the U.

Lung cancer is the second most common type of cancer worldwide, with more than 2 million newly diagnosed patients in 2020

Enhertu is an ADC therapy jointly developed by AstraZeneca and Daiichi Sankyo

This sBLA is based primarily on positive results from the registrational Phase 2 clinical trial DESTINY-Lung01

At a median follow-up of 13.

Dr Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "The DESTINY-Lung01 clinical trial validates HER2 gene mutation as a targetable biomarker in non-small cell lung cancer

References:

[1] Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.